Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib PK in Renal Impairment
NCT02085538Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of palbociclib in breast cancer (4 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time at 8 days and Maximum Observed Plasma Concentration at 8 days. Started May 2014; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02085538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02085538.